Eye Manifestations
8
0
0
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
13%
1 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (8)
Ocular Effects of Synthetic Cannabinoids
Microvascular Ocular Changes of Systemic Lupus Erythematous
The Effect of Upneeq (Oxymetazoline Hydrochloride 0.1%) on Eyelid Position, Eye Redness, and Eye Appearance
Intraoperative OCT Guidance of Intraocular Surgery
Effect of Smokeless Tobacco on Anterior Segment
Comparison of Ectoin® Containing Eye Drops and Ectoin® Containing Eye Spray With the Eye Spray Tears Again®
Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
Ocular Surface Changes in Patients With Cystic Fibrosis